GeoVax Labs (GOVX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Executive summary
Annual Meeting scheduled for June 17, 2026, to elect seven directors and vote on key proposals, including warrant exercises and executive compensation.
Proposals include approval of new share issuances tied to warrant exercises, ratification of the external auditor, and advisory votes on executive pay and its frequency.
Board recommends voting in favor of all proposals and a triennial frequency for say-on-pay votes.
Shareholders of record as of April 20, 2026, are eligible to vote; quorum is one-third of outstanding shares.
Voting matters and shareholder proposals
Election of seven directors to serve until the 2027 Annual Meeting.
Approval of up to 865,804 shares for February 2026 Warrants, 1,269,316 shares for March 2026 Warrants, and 1,702,986 shares for May 2026 Warrants, all requiring shareholder approval under Nasdaq rules.
Ratification of Wipfli LLP as independent auditor for fiscal 2026.
Advisory vote on executive compensation and on the frequency of future say-on-pay votes, with the Board recommending every three years.
Board of directors and corporate governance
Board consists of seven members, with a mix of executive and independent directors.
Committees include Audit, Compensation, and Nominating and Governance, all with independent members.
Board structure combines Chairman and CEO roles; all directors attended at least 75% of meetings in 2025.
Code of Business Conduct and Ethics and insider trading policy in place.
Latest events from GeoVax Labs
- GEO-MVA targets a $1.3B vaccine market gap with expedited approval and scalable U.S. supply.GOVX
Corporate presentation - Net loss narrowed and lead programs advanced, but cash runway and funding risks remain.GOVX
Q2 2026 - Expedited vaccine and oncology programs target global supply gaps and major market opportunities.GOVX
Corporate presentation - Next-gen COVID-19 and mpox vaccines advance with major funding and global supply ambitions.GOVX
H.C. Wainwright 26th Annual Global Investment Conference 2024 - GEO-MVA advances to phase III with expedited EMA review, targeting unmet global vaccine demand.GOVX
Investor update - Biotech advancing late-stage vaccine and cancer therapy faces funding and regulatory risks.GOVX
Registration filing - BARDA awarded nearly $400M for a pivotal COVID-19 vaccine trial; cash runway ends after Q3 2024.GOVX
Q2 2024 - Q1 2025 revenue rose to $1.6M, but contract loss and cash runway raise going concern risks.GOVX
Q1 2025 - BARDA-backed vaccine and oncology advances drive 2024 results and set up key 2025 milestones.GOVX
Q4 2024